Network

Greg is the owner of GE Consulting, providing BioPharma product/CMC development solution to a portfolio of SME and startup ventures.

Greg has a degree in molecular biology and a PhD in molecular immunology. Greg has more than 25 years’ experience in the BioPharma industry, having with a strong track record of designing and executing development strategies for innovate biologics based on cutting edge technologies, whilst building and providing leadership to dedicated teams of SMEs and program heads.

Greg’s previous experience includes:

• VP Biologics CMC at Glenmark Pharmaceuticals. Led a department of 75+ scientists and engineers responsible for cascading strategy for the development and production of a pipeline of multiple mAb, bispecific and biosimilar products.
• CMC/Bioprocess Sciences, Product Discovery/Development Department head (20+ scientists and engineers) at NovImmune SA responsible for the development of a pipeline of multiple mAb and bispecific products
• Discovery Scientist at Pierre Fabre Biologics Centre
• Discovery Scientist at the Glaxo Biomedical Research Institute
• PhD Molecular Biology, U Manchester, UK

Gordon is the owner of Apex Biologics Consulting, providing BioPharma product/CMC development solution.

Gordon has a degree in Genetics and Cell Biologics and a PhD in Molecular Microbiology.

Gordon is an expert in regulatory and development CMC with more than twenty-three years experience (Technical Project Leader and Global Programme Technical Director at Novartis, Head of Manufacturing at NeuTec Pharma, Senior Consultant at Parexel and VP Alliance and Programme Management at Abzena).

Gordon is an expert in the production of monoclonal antibodies, antibody fragments, growth factors, PEG proteins, biosimilars and antibody drug conjugates; formulation development; processing technology; cell culture; microbial cell substrate genetics & production technology; support for due diligence activities world-wide. Gordon has been involved in numerous clinical trial and BLA/MAA applications and has experience of supporting projects at Health Authority Scientific Advice meetings, BWP and CHMP oral hearings.

www.apexbiologics.co.uk

Let by Dr. Matthias Machacek, LYO-X is a globally operating company based in Basel, Switzerland specialising in PK/PD, Modeling & Simulation and Quantitative Systems Pharmacology for the preclinical and clinical development of biologics, gene therapies, oligonucleotides and other advanced drug formats.

Based near Edinburgh in Scotland, UK, ForthTox Ltd is a dynamic and proactive consultancy firm, with a broad range of toxicological expertise in:

• Pharmaceutical development 
• Medical device development
• Chemicals (REACH)
• In Silico Toxicology
  • Including ICH M7 compliant assessments
• General toxicological consultancy
  • Legal toxicology
  • Occupational toxicology
  • Training in toxicology and CPD

Founded in 2001, and incorporated in 2003 as APAHW Consulting Ltd, by Adam Woolley.

iBx works with a small team of board-certified toxicological pathologists, all are industry veterans with more than 30+ years’ experience in drug development.  iBx uses their expertise to assist clients with general pathology support and to provide specialist advice in recognised areas of expertise for study-specific issues.

Please contact Dr Sarah Taplin to discuss.

KinDyn provides expertise in pharmacokinetics (PK) and pharmacodynamics (PD) to the biopharmaceutical industry for both small molecular weight new chemical entities (NCEs) and biologics (Bx).  With experience across all phase of drug development KinDyn can help apply these principles to guide the development process.